dc.contributor.author |
Prachayasittikul V. |
|
dc.contributor.author |
Pingaew R. |
|
dc.contributor.author |
Nantasenamat C. |
|
dc.contributor.author |
Prachayasittikul S. |
|
dc.contributor.author |
Ruchirawat S. |
|
dc.contributor.author |
Prachayasittikul V. |
|
dc.date.accessioned |
2021-04-05T03:32:43Z |
|
dc.date.available |
2021-04-05T03:32:43Z |
|
dc.date.issued |
2014 |
|
dc.identifier.issn |
11778881 |
|
dc.identifier.other |
2-s2.0-84906242390 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/13933 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906242390&doi=10.2147%2fDDDT.S67300&partnerID=40&md5=d64004a46e7e454a5c2b0953427933b9 |
|
dc.description.abstract |
Purpose: Estrogens play important roles in the pathogenesis and progression of breast cancer as well as estrogen-related diseases. Aromatase is a key enzyme in the rate-limiting step of estrogen production, in which its inhibition is one strategy for controlling estrogen levels to improve prognosis of estrogen-related cancers and diseases. Herein, a series of metal (Mn, Cu, and Ni) complexes of 8-hydroxyquinoline (8HQ) and uracil derivatives (4-9) were investigated for their aromatase inhibitory and cytotoxic activities. Methods: The aromatase inhibition assay was performed according to a Gentest™ kit using CYP19 enzyme, wherein ketoconazole and letrozole were used as reference drugs. The cytotoxicity was tested on normal embryonic lung cells (MRC-5) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: Only Cu complexes (6 and 9) exhibited aromatase inhibitory effect with IC50 0.30 and 1.7 μM, respectively. Cytotoxicity test against MRC-5 cells showed that Mn and Cu complexes (5 and 6), as well as free ligand 8HQ, exhibited activity with IC50 range 0.74-6.27 μM. Conclusion: Cu complexes (6 and 9) were found to act as a novel class of aromatase inhibitor. Our findings suggest that these 8HQ-Cu-uracil complexes are promising agents that could be potentially developed as a selective anticancer agent for breast cancer and other estrogen-related diseases. © 2014 Prachayasittikul et al. |
|
dc.subject |
3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide |
|
dc.subject |
5 nitrouracil |
|
dc.subject |
8 quinolinol |
|
dc.subject |
aromatase |
|
dc.subject |
aromatase inhibitor |
|
dc.subject |
copper complex |
|
dc.subject |
doxorubicin |
|
dc.subject |
iodouracil |
|
dc.subject |
ketoconazole |
|
dc.subject |
letrozole |
|
dc.subject |
manganese derivative |
|
dc.subject |
metal complex |
|
dc.subject |
nickel complex |
|
dc.subject |
unclassified drug |
|
dc.subject |
uracil derivative |
|
dc.subject |
8 quinolinol |
|
dc.subject |
aromatase inhibitor |
|
dc.subject |
coordination compound |
|
dc.subject |
copper |
|
dc.subject |
letrozole |
|
dc.subject |
manganese |
|
dc.subject |
nickel |
|
dc.subject |
nitrile |
|
dc.subject |
triazole derivative |
|
dc.subject |
uracil |
|
dc.subject |
analytical equipment |
|
dc.subject |
antineoplastic activity |
|
dc.subject |
article |
|
dc.subject |
breast cancer |
|
dc.subject |
drug cytotoxicity |
|
dc.subject |
drug structure |
|
dc.subject |
embryo |
|
dc.subject |
enzyme assay |
|
dc.subject |
enzyme inhibition |
|
dc.subject |
human |
|
dc.subject |
human cell |
|
dc.subject |
IC 50 |
|
dc.subject |
lung alveolus cell |
|
dc.subject |
structure analysis |
|
dc.subject |
cell line |
|
dc.subject |
chemistry |
|
dc.subject |
comparative study |
|
dc.subject |
cytology |
|
dc.subject |
drug effects |
|
dc.subject |
IC50 |
|
dc.subject |
lung |
|
dc.subject |
Aromatase Inhibitors |
|
dc.subject |
Cell Line |
|
dc.subject |
Coordination Complexes |
|
dc.subject |
Copper |
|
dc.subject |
Humans |
|
dc.subject |
Inhibitory Concentration 50 |
|
dc.subject |
Ketoconazole |
|
dc.subject |
Lung |
|
dc.subject |
Manganese |
|
dc.subject |
Nickel |
|
dc.subject |
Nitriles |
|
dc.subject |
Oxyquinoline |
|
dc.subject |
Triazoles |
|
dc.subject |
Uracil |
|
dc.title |
Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinolineand uracil derivatives |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Drug Design, Development and Therapy. Vol 8, (2014), p.1089-1096 |
|
dc.identifier.doi |
10.2147/DDDT.S67300 |
|